Advanced Search

 

Study ID Status Title Patient Level Data
C93-078 Completed A study to investigate the effect of oral sumatriptan on the intraocular pressure of healthy subjects.
C93-081 Completed A study to investigate the pharmacokinetics of oral GR85548 in subjects with impaired renal function.
C93-085 Completed A study to assess the pharmacokinetics of inhaled fluticasone propionate from a dry powder formulation using the Diskhaler® upon repeat dosing.
C93-087 Completed A study to investigate whether alcohol has an effect on the safety, tolerability, pharmacokinetics or pharmacodynamics of GR85548.
C93-097 Completed A study to determine the dose equivalence for systemic effects for salmeterol compared with salbutamol given by MDI in healthy subjects.
C94-016 Completed A study to investigate the effect of 6mg subcutaneous sumatriptan on oesophageal motility.
C94-027 Completed A Study to Assess the Absolute Bioavailability of Fluticasone Propionate after Oral Doses (0.1 mg, 1 mg, 10 mg)
C94-034 Completed A study to determine the absolute bioavailability of oral GR85548A.
C94-036 Completed An ascending dose, parallel group study to compare the effects of oral GR85548A on blood pressure in healthy subjects and in hypertensive patients taking anti-hypertensive therapy.
C94-042 Completed A Study to Assess the Absolute Bioavailability of a Single Dose of Inhaled Fluticasone Propionate Administered Via Nebulisation
C94-045 Completed A study to investigate the potential central function effect of GR85548.
C94-057 Completed A study to investigate the effects of the monoamine oxidase A inhibitor, moclobemide, on the pharmacokinetics, safety and tolerability of oral sumatriptan.
C94-071 Completed A study to investigate the safety, tolerability and pharmacokinetics of repeat dosing with oral GR85548A for 5 days.
C95-036 Completed A study to investigate the pharmacokinetics of oral naratriptan (GR85548A) in subjects with impaired hepatic function.
CAE10004 Completed A study to determine the bioequivalence of reformulated 125mg/5mL cefuroxime axetil oral suspension (CAOS) to standard marketed 125mg/5mL suspension at a dose of 250mg. Study Listed on ClinicalStudyDataRequest.com
CAE10005 Completed A study to determine the bioequivalence of reformulated 250mg/5mL cefuroxime axetil oral suspension (CAOS) to standard marketed 250mg/5mL suspension. Study Listed on ClinicalStudyDataRequest.com
CAE40408 Completed An open-label study of sequential therapy with intravenous cefuroxime followed by oral cefuroxime axetil for the treatment of community acquired pneumonia (CAP)
CAL.201 Completed A multicenter, randomized, double-blind study of the safety and efficacy of emulsion formulation calcipotriene foam 0.005% vs vehicle foam, dovonex; (calcipotriene) ointment 0.005% and vehicle ointment in the treatment of mild to moderate plaque-type psoriasis
CAL.203 Completed A randomized, open-label study to assess the bioavailability of emulsion formulation calcipotriene foam, 0.005%, and dovonex® ointment, 0.005%, in patients with mild to moderate plaque-type psoriasis
CAL10001 Completed An Evaluation of the Bioequivalence of a Combined Formulated Tablet (600mg/300mg abacavir/lamivudine) Compared to ZIAGEN† (abacavir) 2 X 300mg Tablets and EPIVIR† (lamivudine) 2 X 150mg Tablets Administered Concurrently and the Effect of Food on Absorption of the Combined Formulation in Healthy ...
CAL102120 Completed An open-label, two-period, crossover, pharmacokinetic study of abacavir and its intracellular anabolite carbovir triphosphate following once-daily and twice-daily administration of abacavir in HIV-infected subjects.
CAL30001 Completed A phase III, randomized, open-label, parallel, multicenter study to evaluate treatment with fixed-dose combination of abacavir/lamivudine (600mg/300mg) once-daily versus abacavir (300mg) twice-daily and lamivudine (300mg) once-daily in combination with tenofovir once-daily and a new PI or NNRTI for 48 weeks in ART-experienced HIV-1 infected patients
CAR 8902 Completed Report of a study to assess the effects of inhibition and induction of hepatic mixed function oxidase activity on the pharmacokinetics of a single oral dose of carvedilol in 8 healthy volunteers.
CAR-02 Completed A Study of the Pharmacodynamics and Pharmacokinetics of Intravenous Carvedilol in Normal Volunteers.
CAZF4005 Completed Treatment of severe infection with ceftazidime (CAZ) continuous infusion in intensive care patients with continuous veno-venous hemodiafiltration

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.